Net sales for the quarter increased 20% to $3.4 billion, compared to $2.82 billion in the second quarter of 2008.

For the first half of 2009, Teva reported a net income attributable to the company of $972 million, or $1.09 per diluted share, compared to $672 million, or $0.82 per diluted share, for the corresponding period of 2008. The company reported net sales of $6.55 billion for the six months ended June 30, 2009, compared to $5.4 billion for the same period of 2008.

Shlomo Yanai, Teva's president and CEO, said: "This was another great quarter for Teva, with record-breaking financial results. This was also an exciting quarter in terms of strategic achievements, as the Barr integration continues to run ahead of schedule and we are realizing more synergies more quickly than we had initially forecast."

A service of YellowBrix, Inc.